[1]
Breman, J.G.; Egan, A.; Keusch, G.T. The intolerable burden of malaria: A new look at the numbers. Am. J. Trop. Med. Hyg., 2001, 64, 4-7.
[2]
Na-Bangchang, K.; Congpuong, K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J. Exp. Med., 2007, 211, 99-113.
[3]
Wernsdorfer, W.H. Epidemiology of drug resistance in malaria. Acta Trop., 1994, 56, 143.
[4]
Sijwali, P.S.; Rosenthal, P.J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in haemoglobin hydrolysis by Plasmodium falciparum. Proc. Nat. Acad. Sci. USA, 2004, 101, 4384-4389.
[5]
Sijwali, P.S.; Shenai, B.R.; Gut, J.; Singh, A.; Rosenthal, P.J. Expression and characterization of the Plasmodium falciparum hemoglobinase falcipain-3. Biochem. J., 2001, 360, 481-489.
[6]
Shenai, B.R.; Sijwali, P.S.; Singh, A.; Rosenthal, P.J. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem., 2000, 2759, 29000-29010.
[7]
Ndakala, A.J.; Gessner, R.K.; Gitari, P.W.; October, N.K.; White, L.; Hudson, A.; Fakorede, F.D.; Shackleford, M.; Kaiser, M.; Yeates, C.; Charman, S.A.; Chibale, K. Antimalarial pyrido[1,2-a] benzimidazole. J. Med. Chem., 2011, 54, 4581-4589.
[8]
Kerr, I.D.; Lee, J.H.; Pandey, K.C.; Harrison, A.; Sajid, M.; Rosenthal, P.J.; Brinen, L.S. Structure of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J. Med. Chem., 2009, 52, 852-857.
[9]
Rosenthal, P.J.; McKerrow, J.H.; Aikawa, M.; Nagasawa, H.; Leech, J.H. A malaria cysteine proteinase is necessary for haemoglobin degradation by Plasmodium falciparum. J. Clin. Invest., 1988, 82, 1560-1566.
[10]
Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Brömme, D. Vinylsulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem., 1995, 38, 3193-3196.
[11]
Schlitzer, M. Antimalarial drugs-what is in use and what is in pipeline. Arch. Pharm. , 2008, 341, 149-163.
[12]
Rosenthal, P.J.; Olson, J.E.; Lee, G.K.; Palmer, J.T.; Klaus, J.L.; Rasnickm, D. Antimalarial effects of vinyl sulfone cysteine protease inhibitors. Antimicro. Agents Chemother., 1996, 40, 1600-1603.
[13]
Lill, M.A. Multi-dimensional QSAR in drug discovery. Drug Discov. Today, 2007, 12, 1013-1017.
[14]
Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
[15]
Phase version 9.4, Schrodinger, LLC, New York, USA 2009.
[16]
Canvas version 9.4, Schrodinger, LLC, New York, USA 2009.
[18]
Marijana, H.; Gordana, P.; Marko, M.; Marijeta, K.; Grace, K-Z. Eur. J. Med. Chem., 2010, 45, 2405-2417.
[19]
Bohets, H.; Annaert, P.; Mannens, G.; Van, B.L.; Anciaux, K.; Verboven, P.; Meuldermans, W.; Lavrijsen, K. Curr. Top. Med. Chem., 2001, 1, 367-383.
